EP1−/ − |
No effect on MLR (10) |
↓ Early and AOM-induced colon cancer (24) |
|
|
↓ Airway responsiveness (27) |
↓ Inflammationdependent fever (26)
↓ NMDA- induced stroke (28) |
|
↓ Gastric mucosal integrity (25) |
EP2−/ − |
↓ PGE2-dependent MLR inhibition (10) |
↓ skin and colon tumors (12, 15)
↓ Tumor angiogenesis (13)
↓ Mammary gland hyperplasia (14) |
↓ Ovulation and fertilization (11) |
↓ Hypotensive effect of PGE2 (9)
Saltsensitive hypertension (9)
↓ Renin secretion rate (9) |
↓ PGE2- induced bronchodilation (9) |
↓ Spinal PGE2-evoked hyperalgesia (16)
↑Stroke after artery occlusion or NMDA (17, 18) |
↓ Osteoclastogenic response to PGE2, PTH, and 1,25- OH Vitamin D3 (9) |
|
EP3−/ − |
↑Allergic inflammation (21)
No effect on MLR (10) |
↑Colon cancer development induced by AOM (22) |
|
↓ Capacity of urinary concentration (23) |
|
↓ Pyrogen-dependent fever (23) |
|
No effect on gastric mucosal protection (25)
Acid induced bicarbonate secretion from duodenum (23) |
EP4−/ − |
↓ Arthritis (9) ↓ PGE2-dependent MLR inhibition (10)
↓ Migration of APC cells (9)
↓ Skin hypersensitivity
|
↓ Aberrant colic foci by AOM (9) |
|
↓ Renin secretion rate (9) |
|
↑Infarct in ischemiareperfusion injury (20) |
↓ Bone mass (9)
↓ Repair from fractures (19) |
↓ Intestine mucosal barrier (25) |